Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NTRX-07 in Mild Cognitive Impairment or Mild to Moderate Alzheimer's Disease
NCT07058688Phase 2Completed
- Sponsor
- NeuroTherapia, Inc.
- Start
- Mar 2025
- Primary completion
- Feb 2026
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial of NTRX-07 in Alzheimer's disease (AD) and Mild Cognitive Impairment (MCI) (2 arms), sponsored by NeuroTherapia, Inc. Primary endpoint: Adverse Events at 6 weeks. Started Mar 2025; status: completed.
02
Drugs
NTRX-07
03
Conditions
Alzheimer's disease (AD)Mild Cognitive Impairment (MCI)
Beyond the preview
Go deeper on NCT07058688.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07058688.